This blog is part one in a series exploring how to leverage real world data to transform brand planning, launch and management created in collaboration with Fierce Pharma.  The problem: Historical methodologies for targeting, marketing and commercial launch are no longer sufficient to ensure that those patients who could benefit the most from a new…

Healthcare today is evolving into precision medicine, or what the FDA refers to as personalized medicine.  To stay competitive in the constantly shifting healthcare landscape, organizations across the healthcare ecosystem must embrace this targeted approach and leverage the tools needed to make safe decisions for their patients or populations. By unlocking insights provided from advanced…

PurpleLab was selected to present a poster at PMSA 2024 on imputing SDOH information on pharmacy claims. This study was centered around prescription fill rates of Semaglutides in the adolescent population. In December of 2022, the FDA approved adolescents BMI at or above the 95th percentile eligible for a Semaglutide prescription. PurpleLab used a combination…

A large CRO has incorporated PurpleLab data directly into their workflow to support all therapeutic areas and phases of clinical trial work from RWE and pre-award through phase IV and beyond including market access and HEOR work. This strategy has been incorporated for all of their clients.  “The data and services provided by PurpleLab have…

Payers are continuously looking to improve health outcomes. Removing barriers to care and improving care access through analyzing social determinants of health (SDOH) data is a key strategy. The social determinants of health (SDOH) include education, housing, transportation, income as well as other factors including where people are born, raised, live and work that impact their…

Semaglutide has gone viral. Ozempic and other glucagon-like peptide-1 (GLP-1) receptor agonists are so popular that more than 24 million Americans—about 7% of the population—could be taking them for weight loss by 2035, according to the latest estimates. The medications have been hailed as “a significant leap forward in tackling obesity,” which affects 41.9% of…

This blog is part two in a series exploring the use of real-world evidence to produce meaningful insights in clinical pharma.  Pharmaceutical manufacturers do more than just produce medications that line pharmacy and hospital shelves: they also need to closely observe and respond to market conditions, changing clinical guidelines, and safety regulations, to ensure that…

This blog is part one in a series exploring the use of real-world evidence to produce meaningful insights in clinical pharma.  Clinical trials are crucial for developing new medications and treatments, but they require meticulous pre-planning and feasibility assessments, which can be extremely time-consuming. Real-world evidence (RWE) offers a promising solution to expedite this process….

Creating a holistic direct to consumer (DTC) and healthcare provider (HCP) marketing strategy from scratch is a demanding task, especially if you don’t have the clinical expertise to precisely identify the consumers or providers you should be targeting. We’re here to give you 5 simple steps to creating a holistic DTC and HCP targeting strategy…